Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on ...

Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more ...

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that ...

After experiencing high growth in the U.S. telehealth scene, Hims is taking its personalized obesity treatments ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.